<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="692">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05152147</url>
  </required_header>
  <id_info>
    <org_study_id>ZWI-ZW25-301</org_study_id>
    <secondary_id>2021-000296-36</secondary_id>
    <nct_id>NCT05152147</nct_id>
  </id_info>
  <brief_title>A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers</brief_title>
  <acronym>HERIZON-GEA-01</acronym>
  <official_title>A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zymeworks Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BeiGene, Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zymeworks Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to find out if zanidatamab, when given with chemotherapy plus or&#xD;
      minus tislelizumab, is safe and works better than trastuzumab given with chemotherapy.&#xD;
&#xD;
      The patients in this study will have advanced human epidermal growth factor 2 (HER2)-positive&#xD;
      stomach and esophageal cancers that are no longer treatable with surgery (unresectable) or&#xD;
      chemoradiation, and/or have grown or spread to other parts of the body (metastatic).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">July 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>multi-cohort, open-label, multicenter study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS) by blinded independent central review (BICR)</measure>
    <time_frame>Up to 2.5 years</time_frame>
    <description>The time from randomization to the date of documented disease progression (per Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) as assessed by BICR or death from any cause</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 3.5 years</time_frame>
    <description>The time from randomization to death due to any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Confirmed objective response rate (ORR) by BICR</measure>
    <time_frame>Up to 2.5 years</time_frame>
    <description>Number of patients who achieved a best overall response of complete response (CR) or (PR) as determined per RECIST 1.1 as assessed by BICR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) by BICR</measure>
    <time_frame>Up to 2.5 years</time_frame>
    <description>The time from the first objective response (CR or PR) per BICR to documented progressive disease per RECIST 1.1 as assessed by BICR or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS per Investigator assessment</measure>
    <time_frame>Up to 2.5 years</time_frame>
    <description>The time from randomization to the date of documented disease progression (per RECIST 1.1) as assessed by Investigator or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR per Investigator assessment</measure>
    <time_frame>Up to 2.5 years</time_frame>
    <description>Number of patients who achieved a best overall response of CR or PR as determined per RECIST 1.1 as assessed by Investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR per Investigator assessment</measure>
    <time_frame>Up to 2.5 years</time_frame>
    <description>The time from the first objective response (CR or PR) per Investigator to documented progressive disease per RECIST 1.1 as assessed by Investigator or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Number of subjects who experienced adverse events or serious adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinical laboratory abnormalities</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Number of patients who experienced a maximum severity of Grade 3 or higher post-baseline laboratory abnormality, including either hematology or chemistry. Grades are defined using National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life (HRQoL) as assessed by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (core cancer questionnaire) C30 (QLQ-C30)</measure>
    <time_frame>Up to 2.5 years</time_frame>
    <description>Changes from baseline in the EORTC QLQ-C30 scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HRQoL as assessed by the EORTC Quality of Life Questionnaire (oesophago-gastric module) OG25 (QLQ-OG25)</measure>
    <time_frame>Up to 2.5 years</time_frame>
    <description>Changes from baseline in the EORTC QLQ-OG25 scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HRQoL as assessed by the EuroQol 5-dimensions 5-levels (EQ-5D-5L) questionnaire</measure>
    <time_frame>Up to 2.5 years</time_frame>
    <description>Changes from baseline in the EORTC EQ-5D-5L questionnaire scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of zanidatamab, tislelizumab, and trastuzumab</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibodies (ADAs)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Number of patients who develop ADAs</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">714</enrollment>
  <condition>Gastric Neoplasms</condition>
  <condition>Gastroesophageal Adenocarcinoma</condition>
  <condition>Esophageal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trastuzumab (Herceptin®) plus physician's choice of capecitabine plus oxaliplatin (CAPOX) or 5-fluorouracil (5-FU) plus cisplatin (FP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zanidatamab plus physician's choice of CAPOX or FP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zanidatamab and tislelizumab plus physician's choice of CAPOX or FP</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zanidatamab</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <other_name>ZW25</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tislelizumab</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Arm C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Administered intravenously (IV)</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Herceptin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Administered orally (PO bid)</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fluorouracil</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>In situ hybridization (ISH)-based companion diagnostic assay</intervention_name>
    <description>Subjects will be tested for HER2 gene-amplification using the ISH-based companion diagnostic assay</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Immunohistochemistry (IHC)-based companion diagnostic assay</intervention_name>
    <description>Subjects will be tested for HER2 protein-expression using the IHC-based companion diagnostic assay</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed unresectable locally advanced, recurrent or metastatic&#xD;
             HER2-positive gastroesophageal adenocarcinoma (adenocarcinomas of the stomach or&#xD;
             esophagus, including the gastroesophageal junction), defined as 3+ HER2 expression by&#xD;
             IHC or 2+ HER2 expression by IHC with ISH positivity per central assessment. Subjects&#xD;
             with esophageal adenocarcinoma must not be eligible for combined chemoradiotherapy at&#xD;
             the time of enrollment&#xD;
&#xD;
          -  Assessable (measurable or non-measurable) disease as defined by RECIST 1.1&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1, assessed&#xD;
             within 3 days prior to randomization&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) ≥ 50% as determined by either echocardiogram&#xD;
             or multiple gated acquisition scan (MUGA)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with a HER2-targeted agent, with the exception of subjects who&#xD;
             received HER2-targeted treatment for breast cancer &gt; 5 years prior to initial&#xD;
             diagnosis of GEA&#xD;
&#xD;
          -  Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2 or any other antibody or&#xD;
             drug specifically targeting T-cell co-stimulation or checkpoint pathways&#xD;
&#xD;
          -  Prior treatment with systemic antineoplastic therapy for unresectable locally&#xD;
             advanced, recurrent or metastatic GEA&#xD;
&#xD;
          -  Untreated central nervous system (CNS) metastases, symptomatic CNS metastases, or&#xD;
             radiation treatment for CNS metastases within 4 weeks prior to randomization. Stable,&#xD;
             treated brain metastases are allowed (defined as subjects who are off steroids and&#xD;
             anticonvulsants and are neurologically stable with no evidence of radiographic&#xD;
             progression for at least 4 weeks prior to randomization)&#xD;
&#xD;
          -  Known history of or ongoing leptomeningeal disease (LMD)&#xD;
&#xD;
          -  Known additional malignancy that is not considered cured or that has required&#xD;
             treatment within the past 3 years&#xD;
&#xD;
          -  Known active hepatitis&#xD;
&#xD;
          -  Any history of human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Known SARS-CoV-2 infection; subjects with prior infection that has resolved per local&#xD;
             institutions' requirements and screening guidance are eligible&#xD;
&#xD;
          -  QTc Fridericia (QTcF) &gt; 470 ms&#xD;
&#xD;
          -  Clinically significant cardiac disease, such as ventricular arrhythmia requiring&#xD;
             therapy, uncontrolled hypertension or any history of symptomatic congestive heart&#xD;
             failure (CHF)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Grim, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Zymeworks Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zymeworks Clinical Trial Resource</last_name>
    <phone>206-237-1030</phone>
    <email>medinfo@zymeworks.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dong-A University Medical Center</name>
      <address>
        <city>Busan</city>
        <zip>49201</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sung Yong Oh, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Do-Youn Oh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Irunlarrea 3 Unidad de Ensayos Clinicos</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Virginia Arrazubi Arrula, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 5, 2021</study_first_submitted>
  <study_first_submitted_qc>December 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2021</study_first_posted>
  <last_update_submitted>December 3, 2021</last_update_submitted>
  <last_update_submitted_qc>December 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HER2</keyword>
  <keyword>Bispecific antibody</keyword>
  <keyword>Biparatopic antibody</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Gastric cancers</keyword>
  <keyword>Esophageal cancers</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>FP</keyword>
  <keyword>mFOLFOX6</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>5-FU</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>Gastroesophageal adenocarcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

